Last $33.56 USD
Change Today +0.15 / 0.45%
Volume 307.1K
ANAC On Other Exchanges
Symbol
Exchange
NASDAQ GM
Berlin
As of 5:20 PM 12/22/14 All times are local (Market data is delayed by at least 15 minutes).

anacor pharmaceuticals inc (ANAC) Snapshot

Open
$33.01
Previous Close
$33.41
Day High
$33.99
Day Low
$32.76
52 Week High
12/8/14 - $37.45
52 Week Low
06/2/14 - $13.19
Market Cap
1.4B
Average Volume 10 Days
709.6K
EPS TTM
$-0.95
Shares Outstanding
42.9M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ANACOR PHARMACEUTICALS INC (ANAC)

anacor pharmaceuticals inc (ANAC) Related Bloomberg News

View More Bloomberg News

anacor pharmaceuticals inc (ANAC) Related Businessweek News

No Related Businessweek News Found

anacor pharmaceuticals inc (ANAC) Details

Anacor Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel small-molecule therapeutics derived from its boron chemistry platform. The company’s lead product candidates include tavaborole, an antifungal product candidate that is in Phase III clinical development for the treatment of onychomycosis; and AN2728, an anti-inflammatory product candidate, which completed Phase II clinical trials for the treatment of atopic dermatitis and psoriasis, and chronic inflammatory skin diseases. It also develops AN5568, a Phase I human clinical trial product targeting human African trypanosomiasis; and other compounds to treat animal health indications. The company’s clinical pipeline also includes AN2718, a topical antifungal product candidate, which is in Phase I clinical trials for the treatment of onychomycosis and fungal infections of the skin; AN2898, a topical anti-inflammatory product candidate that completed Phase IIa clinical trials for the treatment of atopic dermatitis and psoriasis; and AN3365, an antibiotic for the treatment of infections caused by Gram-negative bacteria. It has research, development, and collaboration agreements with GlaxoSmithKline LLC, Eli Lilly and Company, Schering Corporation, Medicis Pharmaceutical Corporation, Bill and Melinda Gates Foundation, and Medicines for Malaria Ventures. The company was formerly known as AnaMax, Inc. and changed its name to Anacor Pharmaceuticals, Inc. in October 2002. Anacor Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Palo Alto, California.

79 Employees
Last Reported Date: 03/17/14
Founded in 2000

anacor pharmaceuticals inc (ANAC) Top Compensated Officers

Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $335.0K
Chief Medical Officer and Senior Vice Preside...
Total Annual Compensation: $335.0K
Senior Vice President of Program Management
Total Annual Compensation: $330.0K
Senior Vice President of Drug Development
Total Annual Compensation: $272.5K
Senior Vice President of Research
Total Annual Compensation: $335.0K
Compensation as of Fiscal Year 2013.

anacor pharmaceuticals inc (ANAC) Key Developments

Anacor Pharmaceuticals, Inc. Announces Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2014

Anacor Pharmaceuticals, Inc. announced unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2014. Revenues for the quarter ended September 30, 2014 were $4.0 million, compared to $3.6 million for the comparable period in 2013. Revenue for the three months ended September 30, 2014 was comprised of $1.1 million of revenue related to the distribution and commercialization agreement with Sandoz (the Sandoz Agreement) and $2.9 million of research contract revenue. Loss from operations was $30.275 million against $15.658 million a year ago. Net loss was $31.342 million or $0.74 per basic and diluted share against net loss of $16.809 million or $0.41 per basic and diluted share a year ago. For the nine months, the company reported total revenue of $11.044 million against $8.743 million a year ago. Loss from operations was $73.805 million against $41.633 million a year ago. Net loss was $77.022 million or $1.83 per basic and diluted share against net loss of $45.983 million or $1.19 per basic and diluted share a year ago.

Anacor Pharmaceuticals, Inc. to Report Q3, 2014 Results on Nov 06, 2014

Anacor Pharmaceuticals, Inc. announced that they will report Q3, 2014 results at 5:00 PM, US Eastern Standard Time on Nov 06, 2014

Anacor Pharmaceuticals, Inc., Q3 2014 Earnings Call, Nov 06, 2014

Anacor Pharmaceuticals, Inc., Q3 2014 Earnings Call, Nov 06, 2014

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ANAC:US $33.56 USD +0.15

ANAC Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ANAC.
View Industry Companies
 

Industry Analysis

ANAC

Industry Average

Valuation ANAC Industry Range
Price/Earnings 26.7x
Price/Sales 72.4x
Price/Book 22.6x
Price/Cash Flow 26.7x
TEV/Sales 64.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ANACOR PHARMACEUTICALS INC, please visit www.anacor.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.